Redirecting Cisplatin and Doxorubicin to Mitochondria Affords Highly Effective PlatinumIV Prodrug Against Triple Negative Breast Cancer.

Nafees MuhammadTan Cai-PingSadia NasreenZong-Wan Mao

Published in: Chemistry, an Asian journal (2021)

A mitochondria targeting dual-action platinumIV prodrug exhibits high anticancer activity in triple negative breast cancer cells. The complex intervenes in several cellular processes including DNA damage, perturbation of mitochondrial bioenergetics and induction of necrosis to kill cancer cells.

Keyphrases

cancer therapy
dna damage
breast cancer cells
oxidative stress
drug delivery
cell death
endoplasmic reticulum
reactive oxygen species
dna repair
drug release